EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.

@article{Hamilton2002EORTC1A,
  title={EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.},
  author={Anne Hamilton and Laura Biganzoli and Robert Coleman and Louis Mauriac and Philippe Hennebert and Ahmad Awada and Marianne A. Nooij and L. Beex and Martine J. Piccart and Ir{\`e}ne Van Hoorebeeck and Peter F Bruning and Dominique de Valeriola},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2002},
  volume={13 6},
  pages={910-8}
}
BACKGROUND We performed a phase I study of polyethylene glycol (pegylated, Stealth) liposomal doxorubicin (Caelyx, Doxil) using a prolonged (6-week) dose interval to reduce the incidence of skin toxicity that was dose-limiting at more conventional dose intervals, and which appeared to be schedule dependent. PATIENTS AND METHODS Eligible for the study were metastatic breast cancer patients who had received a maximum of one prior therapy for metastatic disease. The defined dose levels were 60… CONTINUE READING
30 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…